2023 / 02

Next Paper
DOI: 10.24075/brsmu.2023.010

ORIGINAL RESEARCH

Comparison of the oncolytic activity of recombinant vaccinia virus strains LIVP-RFP and MVA-RFP against solid tumors

Shakiba Y1,2, Naberezhnaya ER1,2, Kochetkov DV1, Yusubalieva GM1,3, Vorobyev PO1, Chumakov PM1, Baklaushev VP1,3, Lipatova AV1
About authors

1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

2 Moscow Institute of Physics and Technology, Dolgoprudny, Russia

3 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Correspondence should be addressed: Anastasia V. Lipatova
Vavilova, 32, Moscow, 119991, Russia; moc.liamg@vnaavotapil

About paper

Funding: the development of oncolytic viruses and in vitro experiments were supported by the Russian Science Foundation (Russian Science Foundation grant № 20-75-10157); in vivo experiments were also supported by the Russian Science Foundation (Russian Science Foundation grant № 22-64-00057).

Author contribution: Ya Shakiba — literature analysis, pre-analytical work, in vitro and in vivo experiments, analysis and interpretation of data, preparation of figures and graphs; ER Naberezhnaya — in vitro experiments, data analysis and interpretation; D. V. Kochetkov — animal care, data interpretation; GM Yusubaleva — data visualization, manuscript editing; PO Vorobyev — production of preparative quantities of the virus for in vivo studies; VP Baklaushev — study planning, preanalytical stage of work, data analysis; AV Lipatova — research management, design development of recombinant strains, data interpretation, editing the manuscript.

Compliance with ethical standards: the study was approved by the ethics committee of the EIMB RAS (protocol № 3 dated October 27, 2022). Experiments carried out in accordance with Directive 2010/63/EU of the European Parliament and of the Council of Europe on the protection of animals used for research.

Received: 2023-02-20 Accepted: 2023-04-02 Published online: 2023-04-28
|
  1. Thorne SH, Hwang TH, Kirn DH. Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther. 2005; 7 (4): 359–65.
  2. Ho TY, et al. Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development. Mol Ther Oncolytics. 2021; 22: 85–97.
  3. Kirn DH, et al. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 2008; 68 (7): 2071–5.
  4. Haddad D, et al. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers. Ann Surg Oncol. 2012; 19: 665–74.
  5. Hughes J, et al. Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. Gene Ther. 2015; 22 (6): 476–84.
  6. Shakiba Y, et al. Oncolytic efficacy of a recombinant vaccinia virus strain expressing bacterial flagellin in solid tumor models. Viruses. 2023; 15 (4): 828. DOI: 10.3390/v15040828.
  7. Tysome JR, et al. Lister vaccine strain of vaccinia virus armed with the endostatin–angiostatin fusion gene: an oncolytic virus superior to dl 1520 (ONYX-015) for human head and neck cancer. Hum Gene Ther. 2011; 22 (9): 1101–8.
  8. Smith GL. Vaccinia virus immune evasion. Immunol Lett. 1999; 65 (1–2): 55–62.
  9. Bahar MW, et al. How vaccinia virus has evolved to subvert the host immune response. J Struct Biol. 2011; 175 (2): 127–34.
  10. Smith GL, et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol. 2013; 94 (11): 2367–92.
  11. Shvalov AN, et al. Complete genome sequence of vaccinia virus strain L-IVP. Genome Announc. 2016; 4 (3): e00372–16.
  12. Gentschev I, et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. 2012; 7 (5): e37239.
  13. Shchelkunov SN, et al. Enhancing the protective immune response to administration of a LIVP-GFP live attenuated vaccinia virus to mice. PLoS One. 2021; 10 (3): 377.
  14. Kochneva G, et al. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget. 2016; 7 (45): 74171.
  15. Zonov E, et al. Features of the antitumor effect of vaccinia virus lister strain. Viruses. 2016; 8 (1): 20.
  16. Koval O, et al. Recombinant vaccinia viruses coding transgenes of apoptosis-inducing proteins enhance apoptosis but not immunogenicity of infected tumor cells. Biomed Res Int. 2017; 2017: 3620510. DOI: 10.1155/2017/3620510.
  17. Tkacheva A, et al. Targeted therapy of human glioblastoma combining the oncolytic properties of parvovirus H-1 and attenuated strains of the vaccinia virus. Molecular Genetics, Microbiology and Virology. 2019; 37 (2): 83–91.
  18. Gholami S, et al. Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer. Breast Cancer Res. 2013; 15 (2): R26.
  19. Holloway R, et al. 837P Phase II trial of oncolytic vaccinia virus primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC)(NCT02759588). Annals of Oncology. 2020; 31: 628.
  20. Suter M, et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine. 2009; 27 (52): 7442–50.
  21. Pittman PR, et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. N Engl J Med. 2019; 381 (20): 1897–908.
  22. Gatti-Mays ME, et al. A phase I dose-escalation trial of BNCV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules. Clin Cancer Res. 2019; 25 (16): 4933–44.
  23. Parato KA, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012; 20 (4): 749–58.
  24. Byrd CM, et al. Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus. Methods Mol Biol. 2004: 31–40.
  25. Cotter CA, et al. Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Mol Biol. 2017; 117 (1): 16.16.1–16.16.18.
  26. Ramakrishnan MAJ. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016; 5 (2): 85.
  27. Morgan DM. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol.1998: 179–84.
  28. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24: 148–54.
  29. Cottingham MG, Carroll MW. Recombinant MVA vaccines: dispelling the myths. Vaccine. 2013; 31 (39): 4247–51.
  30. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006; 6 (10): 715–27.
  31. Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res. 2011; 50: 286–93.
  32. Matsuda T, et al. A comparative safety profile assessment of oncolytic virus therapy based on clinical trials. Ther Innov Regul Sci. 2018; 52 (4): 430–7.
  33. Buller RML, et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinasenegative phenotype. Nature. 1985; 317 (6040): 813–5.
  34. Schrörs B, et al. Multi-omics characterization of the 4T1 murine mammary gland tumor model. Front Oncol. 2020; 10: 1195.
  35. Li Z, et al. Immunotherapeutic interventions of triple negative breast cancer. J Transl Med. 2018; 16 (1): 147.